OTCPicks.com Daily Market Movers Digest Midday Report for Tuesday, January 8th AULO, ARGA, CYGX, ITRO
Dallas, TX 1/08/2008 04:53 PM GMT (TransWorldNews)
Our Stocks to Watch today include Aurelio Resource Corporation (OTCBB: AULO), Auriga Laboratories, Inc. (OTCBB: ARGA), CytoGenix, Inc. (OTCBB: CYGX), Itronics Inc. (OTCBB: ITRO)
Visit http://www.otcpicks.com/ to register for our Daily Market Mover’s Digest Newsletter, and Email Stock Watch Alerts.
AURELIO RESOURCE CORPORATION (OTCBB: AULO)
"Up 22.03% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/AULO.php
Aurelio Resource Corporation, an exploration stage company, engages in the acquisition, exploration, and development of mineral properties. It primarily explores for copper, gold, silver, and zinc minerals. The company owns a 100% interest in 31 mining claims on the Hill Copper property located in southeastern Arizona. It also holds an option to earn a 100% interest in 3 mining claims/concessions in Gavilanes property, covering approximately 1,000 hectares situated in the Tamazula District, Durango, Mexico. The company is headquartered in Littleton, Colorado.
January 8 - Aurelio Intercepts 130 Feet Averaging 2.2 Grams of Gold per Metric Ton and 45 Feet of 7 Grams of Gold per Metric Ton at MAN Area of Hill Copper-Zinc Project, Arizona
Aurelio Resource Corporation (OTCBB: AULO) (FWB: F3RA) announced gold assay results from recent drilling in the MAN Area of the Company's wholly owned Hill Copper-Zinc Project, located in the Turquoise Mining District, Cochise County, Arizona.
The fire assay results reported in Table 1 correspond to previously-released copper, zinc, and silver assay information for drill holes BR07-24 and -26 (see November 8, 2007 news release).
Drill hole BR07-25 was assayed for gold between the depths of 235 and 450 feet to determine the gold content of a previously-reported copper/zinc/silver assay interval (175 feet at 1.45% copper, 0.45% zinc and 1.8 parts-per-million (ppm) silver, including 100 ft averaging 2.29% copper, 0.11% zinc and 1.8 ppm silver). Gold assay results were 125 parts-per-billion (ppb) and 160 ppb, respectively, over these intervals. The strongest gold intercept came below this interval, with an average of 188 ppb between 410 feet and 450 feet.
Gold assays for holes BR07-27 and BR07-28 are pending.
The results indicate the presence of significant gold mineralization at the MAN Area.
The Company’s geologists believe that there are probably multiple phases of gold deposition at the Hill project. Establishing the distribution and nature of the gold mineralization will be a primary focus of the next drilling program, scheduled for the first quarter of 2008.
AURIGA LABORATORIES (OTCBB: ARGA)
"Up 42.86% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/ARGA.php
Auriga Laboratories, Inc., a specialty pharmaceutical company, engages in the development of pharmaceutical products for respiratory, dermatology, and psychiatry markets. The company's product line includes Aquoral, a prescription product for the treatment of xerostomia or dry mouth; Zinx for relief of symptoms associated with common cold and allergies; Extendryl for the treatment of cough, cold, and allergy symptoms; and Levall used in the treatment and relief from cough, congestion, and rhinitis associated with respiratory infections, such as the common cold, influenza, bronchitis, and sinusitis. It also offers dermatology products, such as Akurza and Xyralid. The company has product development license agreements with Athlon Pharmaceuticals and Cornerstone Biopharma. Auriga Laboratories was founded in 2005 and is based in Los Angeles, California.
January 7 - Auriga Laboratories Signs Co-Promotion Agreement With MiddleBrook Pharmaceuticals for Keflex(R) 750 mg
Auriga Laboratories, Inc. (OTCBB: ARGA), a specialty pharmaceutical company, announced that the signing of a co-promotion agreement with MiddleBrook Pharmaceuticals, Inc., pursuant to which Auriga will co-promote Keflex® 750 mg capsules (cephalexin capsules, USP), to Primary Care Specialists in the U.S.
Cephalexin, the generic form of Keflex, is the third most prescribed outpatient antibiotic in the U.S., with approximately 25 million prescriptions written annually. Cephalexin is the number-one most prescribed oral cephalosporin antibiotic and is also the number-one recommended oral antibiotic therapy for uncomplicated skin and skin structure infections.
The co-promotion will begin during the 1st Quarter of 2008. "This agreement solidifies Auriga's commitment to enhance our product portfolio. Currently, over 50% of cephalexin prescriptions are written by Primary Care Specialists which makes Keflex® 750 mg a highly synergistic addition to Auriga's current primary care promotional efforts," said Philip S. Pesin, CEO of Auriga.
Keflex (cephalexin capsules, USP) is a first-generation cephalosporin antibiotic shown to be active against strains of both gram-positive and gram-negative aerobes in vitro and in clinical infections. Keflex is indicated for treatment of the following infections: respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections. For more information on Keflex and prescribing information, visit www.middlebrookpharma.com/products_antibiotics/keflex_antibiotics.aspx.
CYTOGENIX INCORPORATED (OTCBB: CYGX)
"Up 15.38% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/CYGX.php
CytoGenix, Inc., a biopharmaceutical company, focuses on the development and commercialization of its technology for identifying and silencing disease causing genes and expressing proteins for applications, such as vaccines. Its technology includes gene silencing techniques applicable to genes from pathogenic organisms or selected genes from a host to prevent the expression of harmful proteins, thereby preventing, or ameliorating disease. The company also develops a cell free process to produce DNA for sale to the biopharmaceutical market. Its products under development include CY301 SIMPLIVIR for prophylactic and neonatal applications; and CY303, an anti-inflammatory product that blocks the activity of an adhesion molecule, known as intercellular adhesion molecule. The company is also developing compounds against methicillin resistant staphylococcus aureaus. It has agreements with Aldevron, LLC to evaluate a synDNA vaccine derived from a plasmid and GE Healthcare Bio-Sciences Corporation that provides reagents for use in the manufacture of vaccines and therapeutic compounds. The company was founded in 1995. It was formerly known as Cryogenic Solutions, Inc. and changed its name to CytoGenix, Inc. in 2000. CytoGenix is based in Houston, Texas.
January 8 - CytoGenix Announces Notice of Allowance in the U.S. for Herpes Patent
CytoGenix, Inc. (OTCBB: CYGX) announced that it has received a Notice of Allowance for a patent on its Herpes composition from the United States Patent and Trademark Office. The allowed patent entitled, “Treatment of HSV-Related Pathologies Using ssDNA,” claims both the composition of matter utilizing the Company’s single stranded DNA (ssDNA) expression vector technology and methods of treatment utilizing the therapeutic compound.
While most pharmacological agents are employed to chemically signal cells to interrupt, reduce production or bind and regulate specific disease-causing proteins, this application of Cytogenix’s novel ssDNA technology directs infected cell(s) to make a short nucleic acid sequence that specifically targets and impedes the activity of a Herpes virus protein needed for viral reproduction. The specificity of this application reduces the possibility of side effects and/or long-term effects and is a more direct approach to targeting the origin of disease rather than merely treating symptoms.
“Allowance of this patent is an important element in our efforts to commercialize our Herpes therapeutic product. With this milestone accomplished, the Company is concentrating its efforts to complete required testing necessary to meet FDA regulations for an Investigational New Drug (“IND”) application leading to clinical trials of its anti-Herpes Simplivir™ product candidate. The Company’s decision to change its process from one using bacteria-based DNA production to its cell-free synDNA™ manufacturing technology has necessitated the process of resubmitting an IND for its Herpes therapeutic product. With necessary funding, the Company will move as quickly as possible towards the completion of this process”, stated Malcolm Skolnick, CytoGenix President and Chief Executive Officer. “We remain confident that our Simplivir product will receive an IND that will allow us to proceed with clinical trials and ultimately to commercialization of this therapeutic.”
Dr. Cindee Ewell, CytoGenix patent counsel, indicated, “Grant of this patent in the United States provides a major step forward in validating the use of our ssDNA expression technology in DNA-based therapeutics and should provide support for allowance of other Company patent applications utilizing similar technology.”
CytoGenix, Inc. is a Houston-based biopharmaceutical company pioneering the new field of gene based medicine and is focused on developing innovative vaccines and therapeutic products using its three proprietary technology platforms: synDNATM non-bacterial production methodology, single stranded DNA (ssDNA) expression, and oligonucleotide based anti-bacterial technologies. CytoGenix currently holds 13 granted patents and 57 international or US pending patent applications claiming methods and materials in connection with these platform technologies.
ITRONICS INCORPORATED (OTCBB: ITRO)
"Up 22.22% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/ITRO.php
Itronics, Inc., through its subsidiaries, operates as an environmental process technology company in the United States. It operates through two segments, GOLD'n GRO Fertilizer and Mining Technical Services. The GOLD'n GRO Fertilizer segment offers fertilizer manufacturing, photochemical recycling, and silver refining services. The Mining Technical Services segment provides mineral project planning and technical services to the mining industry. This segment offers technical services in the areas of mining, geology, mining engineering, mineral economics, material processing, and technology development to the U.S. and foreign mining companies, public utilities, state agencies, the United Nations and the World Bank. It operates in Arizona, California, Colorado, Idaho, Nevada, Oregon, Rhode Island, Washington, and Utah. The company was founded in 1987 and is based in Reno, Nevada.
January 8 - Itronics Gold'n Minerals, a Special Purpose Mining Subsidiary, is Launched
Itronics Inc. (OTCBB: ITRO) (Frankfurt and Berlin Stock Exchanges: ITG) reported that it has formed Itronics Gold'n Minerals, Inc., a special purpose subsidiary, that will acquire gold and mineral properties and invest in Junior Gold and Mineral Companies which provide the opportunity to develop and commercialize environmentally friendly mining and mineral extraction and processing technologies.
Now that Itronics' technical services group, Whitney & Whitney, Inc. has established the global Gold Producing Stocks web site, http://www.insidemetals.com/, it will use this worldwide data base and its extensive mineral property library to identify certain properties and/or companies that the new subsidiary can acquire or invest in at relatively low cost. Properties acquired will be developed or joint ventured, and may be able to utilize Itronics' metal and mineral extraction technologies to achieve environmentally compatible mineral processing.
"Adding this new subsidiary to Itronics integrated group of businesses accomplishes two important objectives for the Company," said Dr. John Whitney, Itronics President. "It creates a third path to large scale growth for Itronics, and it provides Itronics an opportunity to monetize more of its intellectual property for the benefit of its shareholders."
Whitney & Whitney, Inc. will provide management and technical services to the new subsidiary, which will seek multi-mineral properties and make strategic investments in small specialty companies that are in early stage operation development or small scale commercial operation and that have the potential for expansion. A strategic objective is for this subsidiary to become an operating mining division for Itronics, which will utilize advanced environmentally compatible technologies to mine, extract, and sell mineral and metal products from multi-mineral properties.
The Company believes that this expansion will increase the rate of income and asset growth for Itronics' shareholders. The funding plan is to privately place shares in the subsidiary with qualified investors to provide start up capital and then to take it public within a two to three year time frame. The Company believes that this will become the exit strategy for the initial private investors, and it will create measurable market value for Itronics.
Itronics believes that sharply rising gold and silver prices in particular and rising prices for all metals and minerals in general, are providing a strong incentive for investors to fund new mining projects as well as mineral extraction and processing technology development. "With our demonstrated ability to create and commercially establish revolutionary new recycling and chemical process technology, and with Whitney & Whitney's successful track record of assisting mining companies with new mine development, we are confident that Itronics is well positioned to participate in this new and rapidly emerging technology segment," said Dr. Whitney.
Establishing the Itronics Gold'n Minerals is being implemented pursuant to Itronics eight-part, five year business plan that was first summarized in a press release on June 3, 2005.
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover’s Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at email@example.com.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability:
Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has not been compensated by any of the companies covered in this release. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor’s sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.